TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Completion Remission (CR) Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Area Under the Concentration-time Curve, From Time 0 to the Last Measurable Concentration (AUC0-t) of Repaglinide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed concentration (Cmax) of Repaglinide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to reach Cmax (Tmax) of Repaglinide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morphologic changes in meibomian glands
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cell Growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exacerbations of COPD
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Adverse Events Stratified by Overall and Severity
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Experienced Clinically Important Changes in Supine Diastolic and Systolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants Who Experienced Clinically Important Changes in Supine Pulse Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Weekly Average Binge-eating Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Binge Eating Sum Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nucleus Accumbens Signal Intensity in Response to Reward
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Clozapine response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Side effects from clozapine use
Endpoint domain: Adverse events/effects
Primary endpoint: Participant weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concordance of cardiac blood flow measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Overlap of the Continuous Curvilinear Capsulorhexis margin over the IOL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: 400 m run time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects With Solicited Local and Systemic Adverse Reactions After Each Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Oxygen tension (PaO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in diaphragm thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement of circulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Barthel Index improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Participants That Had bRBC Detectable at 70 Days Post-intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Length of Time Differentially Labeled Biotin-labeled RBCs Can be Distinguished From One Another
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: FEV1 Percent Predicted
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Hourly levels of d and l ritalinic acid and methylphenidate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of CD40L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in rate of glucose disposal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in rate of glucose appearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area under the plasma drug concentration-time curve (AUC0-24h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Terminal Half Life (T½ ) of NFC-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prostate cancer survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Daily Proteinuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Invasive blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Predicted 10-year CHD risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time until vaginal partus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Frequency of treatment-emergent adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Serum High Sensitivity C-Reactive Protein (hsCRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of patients admitted to correct level of care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: AUC0-t of midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t of rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-inf of midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-inf of rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of HIV positive persons who initiate treatment with newer antiretroviral drugs
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Monitor changes in plasma CD4+ T-lymphocyte counts among persons exposed to newer individual ARVs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Monitor plasma HIV-RNA responses among persons exposed to newer individual ARVs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with confirmed symptomatic proximal Deep Vein Thrombosis or Pulmonary Embolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Time from treatment initiation to discontinuation of Overactive Bladder (OAB) therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Time from treatment initiation to switching to another OAB therapy or dose
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of participants who discontinue OAB treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: CVC tip distance to right atrium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Objective response rate (ORR) as per RECIST v1.1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Contraceptive continuation rates
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Number of freezing of gait episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of freezing of gait episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from Biliary Stricture Re-intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Reduction in BASDAI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anastomotic Healing Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Half Value Duration (HVD) of surrogate markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ARC incidence per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ARC incidence per admission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ARC daily prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge of melanoma detection
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Identification of known single gene disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of novel genetic disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of recurrence-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Number of patients who had arterial thromboembolism (ATE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Number of patients who had venous thromboembolism (VTE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Number of patients who had major bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: OR Total Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Western Ontario Arthritis of the Shoulder Index (WOOS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Ipsilateral local failure (first event of invasive or DCIS recurrence)
Endpoint domain: Mortality/survival
Primary endpoint: change of protein biomarkers expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change of microRNA-126 expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change of microRNA-146a expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decision on antipsychotic dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mental Health or Substance Use Issue Raised
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mental Health/Substance Use Action Taken
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: HCV infection of the offspring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in percent lean mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Opioid consumption at 24 hours after extubation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Opioid consumption at 6 hours after extubation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change From Baseline in Peak FEV1 (Over 4 Hours)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of patients with a clinical relevant increase of the haemoglobin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: summated xerostomia inventory (SXI) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in lung function parameters (FEV1 & FVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Safety measured as type, frequency and severity of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: pattern of lymph drainage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: delay of lymph drainage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: enhancement of inguinal lymph nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Characterization of clinical disease spectrum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Blood Pressure from Baseline to End of Dosing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of volume change of whole brain and hippocampus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Maternal Morbidity of Second Stage Cesarean Section
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Infant Morbidity of Second Stage Cesarean Section
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Response as assessed by gene expression profiling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Imaging Blood Flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: survival rate of patients treated with OSI-774
Endpoint domain: Mortality/survival
Primary endpoint: Percent of subjects with TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Change in maximal aerobic capacity (VO2max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pathological cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in pain
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: 2-Year Local-Regional Control Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Derecruited volume estimated (Vder,est)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-24 of sitagliptin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cmax of sitagliptin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With Undetectable HCV-RNA at Week 72
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in Limb Blood Flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Discomfort of using TENS
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mood Severity Index
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Negative effort dependence variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early cancer markers in pancreatic juice
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of readmissions related to feeding difficulty
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of readmissions related to aspiration
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Total in-hospital admission rate
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Acceptability of systematic identification
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Impact on management of psychoactive substance use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in ACQ-7 score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of nights with CPAP use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative opioid-consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Sensitivity for 100 HEP/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity for 100 HEP/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived clinical pain
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Detection of brain changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Attention bias
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of self-reported motor symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of self-reported non-motor symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of elevated FC levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: practicability/acceptability of the Stylomax pen
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Feasibility of neoadjuvant Ki-67 and Oncotype DX
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Turnaround time of Ki-67 and Oncotype DX
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Feasibility of MRI prior to neoadjuvant systemic treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Turnaround time of MRI prior to neoadjuvant systemic treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Graft integration by the Signal / Noise Quotient (SNQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevention of postoperative discomfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Best-corrected Visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to epithelial closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage change in focal seizure frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Relapse-free survival (RFS) at 5 years
Endpoint domain: Mortality/survival
Primary endpoint: Type and frequency of molecular alterations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects with no clinically significant bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving Serotype Specific IgG Antibody Concentration ≥0.35 Mcg/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants Achieving Antibody Level ≥5 ELISA Units Per mL for Pertussis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Weight lost
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Relative dose requirement of tacrolimus, ciclosporin or MMF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve (AUCins(0-1h))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Response rate of preoperative XELOX followed by surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Glycated hemoglobin (HbA1C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants That Have Biochemical Cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Feasibility of study design
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Drug-induced liver injury (DILI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Number of deaths within 30 days from emergency laparotomy
Endpoint domain: Mortality/survival
Primary endpoint: New diagnoses of diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: New diagnoses of hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: New diagnoses of cataracts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: New diagnoses of osteoporosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: New diagnoses of avascular necrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Area under the plasma concentration versus time curve (AUC) of GLP-1 and GIP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in genomic and immune biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Level of p-Chk1 and phospho-histone 2AX (p-H2AX)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of Cardiac or unexplained death, new Q-wave MI
Endpoint domain: Mortality/survival
Primary endpoint: Time to door for a confirmed occlusive event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: improvement of peak VO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prognosis of outcome in patients suffering from severe infections
Endpoint domain: Mortality/survival
Primary endpoint: Hair density over the scalp
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Disease-Aggravation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nutrition attitude
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Dietary practices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Optimization of BUSS examination procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Triglyceride-rich lipoprotein production rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants Reporting Solicited Injection Site and Solicited Systemic Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Geometric Mean Titers (GMTs) of Hemagglutination Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti Mullerian hormone (AMH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes